ArashKardanMD
Nuclear Medicine • Houston, TXDivision Chief of Nuclear Medicine and Molecular Imaging Baylor College of Medicine
Dr. Kardan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
7200 Cambridge St
Houston, TX 77030Phone+1 713-798-3924
Summary
- Dr. Arash Kardan is an academic nuclear medicine physician in Houston, TX and is affiliated with Baylor College of Medicine.
Education & Training
Stanford Health CareFellowship, PET/CT Clinical Oncology, 2010 - 2011
Stanford Health Care-Sponsored Stanford UniversityResidency, Nuclear Medicine, 2008 - 2010
Massachusetts General HospitalFellowship, Molecular Imaging, 2006 - 2008- Massachusetts General HospitalFellowship, Nuclear Cardiology, 2004 - 2006
University of Arizona College of Medicine-TucsonResidency, Internal Medicine, 2000 - 2003
New York Medical College at St Vincent's Hospital and Medical Center of New YorkInternship, Transitional Year, 1999 - 2000
New York Medical CollegeFifth Pathway, Medicine, 1999 - 2000
Universidad Autonoma de GuadalajaraClass of 1999
Ohio State UniversityGraduate Studies, Biochemistry, 1994 - 1995
University of MicihiganBS, Biology and Near Eastern Studies, 1989 - 1994
Certifications & Licensure
CA State Medical License 2008 - 2026
TX State Medical License 2022 - 2026
OH State Medical License 2003 - 2022
American Board of Nuclear Medicine Nuclear Medicine
American Board of Nuclear MedicineCertification Board of Nuclear Cardiology
Awards, Honors, & Recognition
- Top Doctors in Houston Houstonia Magazine, 2024
- On Time Doctor Vitals.com, 2014-2015, 2017-2018
- Patient's choice award Vitals.com, 2011, 2014-2015, 2017-2018
- Join now to see all
Clinical Trials
- Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Start of enrollment: 2015 Jan 19
- An Evaluation of the Safety of Intravenous Tc 99m Tilmanocept and a Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH Start of enrollment: 2017 Dec 06
- Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases Start of enrollment: 2020 Oct 26
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsThe predictive impact of dual somatostatin receptor/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tum...Amr Mohamed, Sylvia L Asa, Zhenghong Lee, Sree H Tirumani, Qiubai Li
Journal of Gastrointestinal Oncology. 2023-04-29 - 1 citationsUsing an Assumed Lung Mass Inaccurately Estimates the Lung Absorbed Dose in Patients Undergoing HepaticYttrium Radioembolization Therapy.Cassidy R Dodson, Colin Marshall, Jared C Durieux, Patrick F Wojtylak, Jon C Davidson
Cardiovascular and Interventional Radiology. 2022-12-01 - Abdominopelvic MR to CT registration using a synthetic CT intermediate.Jin Uk Heo, Feifei Zhou, Robert Jones, Jiamin Zheng, Xin Song
Journal of Applied Clinical Medical Physics. 2022-09-01
Journal Articles
- Myocardial Perfusion Imaging: From Diagnosis to PrognosisKardan, A., Primary Care Reports
Books/Book Chapters
Press Mentions
Navidea Biopharmaceuticals to Ring Opening Bell at the New York Stock ExchangeSeptember 28th, 2020- Navidea Biopharmaceuticals Reports Second Quarter 2019 Financial ResultsAugust 8th, 2019
- Navidea Biopharmaceuticals Announces SNMMI Press Release and Recognition of Phase 1/2 Study ResultsJune 24th, 2019
- Join now to see all
Other Languages
- Spanish, Farsi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
